Cullinan Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Cullinan Therapeutics, Inc. (CGEM), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are CGEM insiders buying or selling?
In the last 12 months, Cullinan Therapeutics, Inc. insiders reported 2 open-market purchases ($3.5M) and 24 sales ($2.5M) — net buying of $986.2K. Since January 2021, Trabud has recorded 132 Form 4 filings for CGEM: 12 buys ($51.6M) and 120 sells ($37.4M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $2.1M by Lynx1 Capital Management LP (10% Owner) on Oct 21, 2025. SEC ↗
- The most recent open-market purchase was reported on Oct 30, 2025 (11 months ago).
Key Statistics (January 2021 – Sep 10, 2026)
Total Form 4 filings
132
SEC EDGAR
Insider filers
17
Insider buys (12)
$51.6M
Insider sells (120)
$37.4M
Insider sentiment
Net buyingNet insider flow of $14.2M in net buying since January 2021, and $986.2K in net buying over the last 12 months.
Recent CGEM insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 8.0K | $21.57 | $172.6K | SEC ↗ |
| Aug 14, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 30.0K | $20.26 | $607.8K | SEC ↗ |
| Jul 7, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 8.0K | $17.82 | $142.6K | SEC ↗ |
| May 6, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 8.0K | $14.62 | $117.0K | SEC ↗ |
| Mar 9, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 8.0K | $15.68 | $125.4K | SEC ↗ |
| Feb 26, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 1.8K | $14.14 | $25.2K | SEC ↗ |
| Feb 25, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 5.4K | $14.31 | $76.6K | SEC ↗ |
| Feb 25, 2026 | Nadim Ahmed | President and CEO | Sale | 13.5K | $14.47 | $195.6K | SEC ↗ |
| Feb 25, 2026 | Jeffrey Alan Jones | Chief Medical Officer | Sale | 4.6K | $14.47 | $66.3K | SEC ↗ |
| Feb 25, 2026 | Jacquelyn L Sumer | Chief Legal Officer | Sale | 3.6K | $14.47 | $52.1K | SEC ↗ |
| Feb 23, 2026 | Jeffrey Alan Jones | Chief Medical Officer | Sale | 5.0K | $13.62 | $67.9K | SEC ↗ |
| Feb 23, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 11.7K | $14.08 | $165.4K | SEC ↗ |
| Feb 23, 2026 | Jacquelyn L Sumer | Chief Legal Officer | Sale | 3.7K | $13.62 | $51.0K | SEC ↗ |
| Feb 23, 2026 | Nadim Ahmed | President and CEO | Sale | 16.4K | $13.62 | $223.1K | SEC ↗ |
| Feb 23, 2026 | Mary Kay Fenton | Chief Financial Officer | Sale | 4.4K | $13.62 | $59.9K | SEC ↗ |
| Feb 13, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 416 | $12.03 | $5.0K | SEC ↗ |
| Jan 23, 2026 | Jennifer Michaelson | Chief Scientific Officer | Sale | 4.0K | $12.30 | $49.2K | SEC ↗ |
| Dec 29, 2025 | Nadim Ahmed | President and CEO | Sale | 9.9K | $10.01 | $99.3K | SEC ↗ |
| Dec 22, 2025 | Jennifer Michaelson | Chief Scientific Officer | Sale | 1.3K | $10.01 | $13.5K | SEC ↗ |
| Dec 19, 2025 | Jacquelyn L Sumer | Chief Legal Officer | Sale | 3.5K | $9.67 | $33.7K | SEC ↗ |
| Dec 19, 2025 | Jeffrey Alan Jones | Chief Medical Officer | Sale | 4.6K | $9.67 | $44.8K | SEC ↗ |
| Dec 19, 2025 | Jennifer Michaelson | Chief Scientific Officer | Sale | 2.9K | $9.67 | $28.0K | SEC ↗ |
| Dec 16, 2025 | Jennifer Michaelson | Chief Scientific Officer | Sale | 3.1K | $12.23 | $38.4K | SEC ↗ |
| Nov 25, 2025 | Jennifer Michaelson | Chief Scientific Officer | Sale | 4.0K | $12.30 | $49.2K | SEC ↗ |
| Oct 30, 2025 | Lynx1 Capital Management LP | 10% Owner | Purchase | 165.7K | $8.40 | $1.4M | SEC ↗ |
Showing the 25 most recent of 132 Form 4 filings for Cullinan Therapeutics, Inc..
Most active CGEM insiders
- Jennifer Michaelson41 filings
- Jeffrey Trigilio13 filings
- Jacquelyn L Sumer11 filings
- Jeffrey Alan Jones11 filings
- Nadim Ahmed11 filings
Ask anything about CGEM insider activity
Use Trabud's AI agent to query Cullinan Therapeutics, Inc.'s Form 4 history in plain English — "Show me CGEM CEO purchases this year" or compare it against any other ticker.
Open the AI agentCGEM insider trading FAQ
Are Cullinan Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Cullinan Therapeutics, Inc. insiders reported 2 open-market purchases ($3.5M) and 24 sales ($2.5M) — net buying of $986.2K. Since January 2021, Trabud has recorded 132 Form 4 filings for CGEM: 12 buys ($51.6M) and 120 sells ($37.4M). Over the full record that is net buying of $14.2M.
How many insiders trade CGEM stock?
17 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Cullinan Therapeutics, Inc.. The most recent filing was accepted on Sep 10, 2026.
Where does Trabud get CGEM insider trading data?
All CGEM insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.